MedTrace Logo

Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age

NCT02358811 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2024-03-13

No results posted yet for this study

Summary

Sleep apnea is a common disease in the general population and more particularly in elderly subjects in whom prevalence can reach 30 % after 70 years old. In adults (\<55 years old) cardiovascular consequences are well known and make sleep apnea treatment necessary. However elderly (\>70 years old) apneic subjects are less symptomatic in terms of sleepiness, they usually present a lower index of respiratory events and cardiovascular consequences in this population are still discussed, driving some authors to consider sleep apnea in the elderly as a specific disease and making the need for a treatment questionable.

In this study the investigators will focus on the comparison between adult and elderly apneic subjects in terms of cognitive and cardiovascular consequences. Adult apneic patients suffer from a decrease of cognitive performance as well as grey matter local atrophy, particularly in the hippocampus and in the frontal lobes. According to fewer studies, white matter can also be affected by a demyelinisation process. These structural modifications are sometimes associated with disorders of executive and memory functions. In the elderly, no clear association can be drawn between cognitive decline and sleep apnea. Moreover, to our knowledge, the cerebral state of elderly symptomatic apneic subjects has mostly not be investigated.

Conditions

  • Obstructive Sleep Apnea (SAOS)
  • Aging

Interventions

DEVICE

Magnetic resonance imaging (MRI)

The acquisition of the image will last 45 minutes with 6 sequences. * Before any examination, the manipulator will check the absence of contraindication to MRI. * During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI. * Throughout the examination, a physician will always be present.

BEHAVIORAL

Cognitive assessment

This cognitive assessment will include the following executive tests : * test of Stroop * left Trail Making Test A and B * verbal fluence test * test of memory of figures direct and inverse in order * completion of matrices * Paced Auditory Serial Addition Test (PASAT)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Frederic ROCHE, MD-PhD · CHU de Saint-Etienne

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2023-03-06
Completion
2023-04-14

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02358811 on ClinicalTrials.gov